Part of Yaselle Diaxen – Diabetes & Endocrine Care Division

Dapagliflozin 10 mg + Metformin 500 mg SR (Tab)

Brand Name: TENMESELLE
Dapagliflozin 10 mg + Metformin 500 mg SR (Tab)

Get a Quote
dapagliflozin1
dapagliflozin-10mg2
dapagliflozin3

Product Overview

  • TENMESELLE-SR is a dual metabolic formulation combining Metformin HCL 500 mg (SR) and Dapagliflozin 10 mg. Dapagliflozin selectively inhibits Sodium-Glucose Cotransporter 2 (SGLT2) in proximal renal tubules to block glucose reabsorption and induce insulin-independent urinary glucose excretion (glucosuria). Metformin SR works synergistically to enhance peripheral tissue insulin sensitivity and suppress hepatic glucose production.
  • Designed as a modern combination tablet for Type 2 diabetes, it tackles high blood sugar through two complementary mechanisms. It helps muscles absorb glucose more effectively while signaling the kidneys to flush out excess sugar through urine, supporting both blood sugar control and weight management.
  • Developed under stringent quality standards, TENMESELLE-SR ensures consistent efficacy, safety, and patient compliance — empowering physicians to achieve optimal therapeutic outcomes in Type 2 Diabetes with Cardio-Renal Considerations.

Therapeutic Benefits / Key Features

  • Dual mechanism for improved glycemic control and weight management.
  • SGLT2 inhibition promotes glucose excretion and helps reduce HbA1c.
  • Extended-release Metformin improves tolerance and ensures steady absorption.
  • Demonstrated cardio-renal protective effects in long-term studies.

Brand Composition

Each film-coated tablet contains:

  • Dapagliflozin Propanediol Monohydrate equivalent to Dapagliflozin 10 mg
  • Metformin Hydrochloride I.P. 500 mg (Extended Release)

Why this formulation matters

  • Offers complementary mechanisms of action targeting multiple pathways in diabetes control.
  • Supports better glycemic variability management and weight neutrality.
  • Proven efficacy in reducing cardiovascular risks and improving metabolic outcomes.
  • Once-daily regimen simplifies therapy and enhances compliance.

Division Identity

Part of Yaselle Diaxen – Diabetes & Endocrine Care Division
Empowering better diabetes control through innovation and patient-centric care.